PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 63,411 shares, a growth of 72.2% from the November 30th total of 36,815 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average daily trading volume, of 109,414 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily trading volume, of 109,414 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.5% of the shares of the company are short sold.

PolyPid Stock Performance

PYPD stock traded up $0.32 during midday trading on Monday, hitting $4.39. 183,060 shares of the stock were exchanged, compared to its average volume of 163,835. PolyPid has a fifty-two week low of $2.30 and a fifty-two week high of $4.40. The stock has a market cap of $69.80 million, a price-to-earnings ratio of -1.47 and a beta of 1.49. The stock’s 50-day moving average price is $3.77 and its 200-day moving average price is $3.57.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.17. Research analysts anticipate that PolyPid will post -1.79 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Roth Capital cut their target price on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PolyPid in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

Institutional Trading of PolyPid

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its position in PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares during the last quarter. Lumbard & Kellner LLC acquired a new position in shares of PolyPid in the 2nd quarter valued at $135,000. Finally, AIGH Capital Management LLC grew its stake in shares of PolyPid by 27.0% in the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after purchasing an additional 253,727 shares during the period. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.